MTP XV: CML       

Session Chair: Delphine Rea

• Stopping Therapy (TFR) in the Real World – Which Patients, When and How to Monitor | Jeffrey H Lipton, MD, PhD, FRCPC | University of Toronto, Toronto, Canada
• Defining a TKI Dose – Minimal Effect or Maximal Tolerance | Charles A Schiffer, MD | Wayne State University, Detroit, Michigan, USA
• Atypical CML –Diagnosis and Therapy | Massimo Breccia, MD | Sapienza University, Rome, Italy